REVIEW A dual 5-alpha-reductase inhibitor that blocks both type 1 and type 2 5-alpha-reductase isoenzymes. These enzymes are responsible for converting testosterone into dihydrotestosterone (DHT) in the prostate.
Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, Vaughan ED (2012). Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5a-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol. 188(3):757-61. PMID 22818135.